ASCO Lung Cancer
Conference Coverage
No OS benefit with gefitinib vs. chemo for EGFR+ NSCLC
Adjuvant gefitinib improved disease-free survival, but not overall survival, when compared with standard chemotherapy.
Conference Coverage
Tepotinib elicits responses in METex14 NSCLC
Results with tepotinib establish MET exon 14 as “an actionable target” for non–small cell lung cancer, an investigator said.
Conference Coverage
TKI plus SBRT tops TKI alone for oligometastatic EGFRm NSCLC
Conference Coverage
Pembrolizumab plus EP gives slight PFS edge in ES-SCLC
The KEYNOTE-604 trial showed a small progression-free survival benefit with the addition of pembrolizumab to standard chemotherapy.
Conference Coverage
‘Promising’ durvalumab results spark phase 3 trial in mesothelioma
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
Conference Coverage
Trastuzumab deruxtecan proves active in HER2-mutated NSCLC
The confirmed overall response rate was 61.9%, and the median duration of response has not been reached.
Conference Coverage
First-line nivolumab plus platinum/etoposide effective in extensive-stage SCLC
Conference Coverage
Adjuvant osimertinib extends DFS in localized NSCLC
Osimertinib reduced the risk of disease recurrence or death by 79% in patients with EGFR-mutated non–small cell lung cancer.
Conference Coverage
Quitting smoking just 2 years before lung cancer diagnosis may improve survival